Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis

Metabolism: Clinical and Experimental

Volumn 48, Issue 2, 1999, Pages 233-238

  Verrips, Aad ^a   Wevers, Ron A ^a   Van Engelen, Baziel G M ^a   Keyser, Antoine ^a   Wolthers, Bert G ^a   Barkhof, Frederik ^a   Stalenhoef, Anton ^a   De Graaf, Ruurd ^a   Janssen Zijlstra, Fokje ^a   Van Spreeken, Alwin ^a   Gabreëls, Fons J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHENODEOXYCHOLIC ACID; CHOLESTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ARTICLE; BRAIN SCINTISCANNING; CEREBROTENDINOUS XANTHOMATOSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MALE; ONSET AGE; PRIORITY JOURNAL;

EID: 13044264478     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90040-9     Document Type: Article

References (33)

1. Oftebro H, Bjorkhem I, Stormer FC, et al: Cerebrotendinous xanthomatosis: Defective liver mitochondrial hydroxylation of chenodeoxycholic acid precursors. J Lipid Res 22:632-640, 1981
2. Björkhem I, Boberg KM: Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol, in Scriver C, Beaudet AL, Sly WS, et al (eds): The Metabolic and Molecular Basis of Inherited Disease, vol 7. New York, NY, McGraw-Hill, 1995, pp 2273-2299
3. Ballantyne CM, Vega GL, East C, et al: Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. Metabolism 36:270-276, 1987
4. Wolthers BG, Walrecht HT, van der Molen JC, et al: Use of determinations of 7-lathosterol (5 alpha-cholest-7-en-3 beta-ol) and other cholesterol precursors in serum in the study and treatment of disturbances of sterol metabolism, particularly cerebrotendinous xanthomatosis. J Lipid Res 32:603-612, 1991
5. Wolthers BG, Volmer M, van der Molen J, et al: Diagnosis of cerebrotendinous xanthomatosis (CTX) and effect of chenodeoxycholic acid therapy by analysis of urine using capillary gas chromatography. Clin Chim Acta 131:53-65, 1983
6. Salen G, Meriwether TW, Nicolau G: Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem Med 14:57-74, 1975
7. Berginer VM, Salen G, Shefer S: Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311:1649-1652, 1984
8. Hinman RC: Cerebrotendinous xanthomatosis in Hawaii - A therapeutic failure. Hawaii Med J 43:472-477, 1984
9. Donaghy M, King RH, McKeran RO, et al: Cerebrotendinous xanthomatosis: Clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodeoxycholic acid. J Neurol 237:216-219, 1990
10. Chang WN, Kuriyama M, Chee EC: Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid in three siblings. J Formos Med Assoc 93:256-259, 1994
11. Reiss AB, Martin KO, Rojer DE, et al: Sterol 27-hydroxylase: Expression in human arterial endothelium. J Lipid Res 38:1254-1260, 1997
12. Dotti MG, Garuti R, Calandra S, et al: Clinical and genetic variability in CTX. Eur J Neurol 35:12, 1996 (suppl 5, abstr)
13. Kuriyama M, Tokimura Y, Fujiyama J, et al: Treatment of cerebrotendinous xanthomatosis: Effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci 125:22-28, 1994
14. Salen G, Batta AK, Tint GS, et al: Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis. Metabolism 43:1018-1022, 1994
15. Watts G, Mitchell W, Bending J. et al: Cerebrotendinous xanthomatosis: A family study of sterol 27-hydroxylase mutations and pharmacotherapy. Q J Med 89:55-63, 1996
16. Peynet J, Laurent A, De Liege P, et al: Cerebrotendinous xanthomatosis: Treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings. Neurology 41:434-436, 1991
17. Pedley TA, Emerson RG, Warner CL, et al: Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. Ann Neurol 18:517-518, 1985
18. Nakamura T, Matsuzawa Y, Takemura K. et al: Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 40:741-746, 1991
19. Lewis B, Mitchell WD, Marenah CB, et al: Cerebrotendinous xanthomatosis: Biochemical response to inhibition of cholesterol synthesis. Br Med J Clin Res Ed 287:21-22, 1983
20. Chakraverty S, Griffiths PD, Walls TJ, et al: Cerebrotendmous xanthomatosis in two sisters: Case reports and MR imaging. Clin Radiol 50:117-119, 1995
21. Verrips A, Steenbergen-Spanjers GCH, Luyten JAFM, et al. Exon skipping in the sterol 27-hydroxylase gene leads to cerebrotendinous xanthomatosis. Hum Genet 100:284-286, 1997
22. Garuti R, Lelli N, Barozzini M. et al: Cerebrotendinous xanthomatosis caused by two new mutations of the sterol-27-hydroxylase gene that disrupt mRNA splicing. J Lipid Res 37:1459-1467, 1996
23. Cali JJ, Hsieh CL, Francke U, et al: Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266:7779-7783, 1991
24. Reshef A, Meiner V, Berginer VM, et al: Molecular genetics of cerebrotendinous xanthomatosis in Jews of north African origin. J Lipid Res 35:478-483, 1994
25. Koopman BJ, van der Molen JC, Wolthers BG, et al: Capillary gas Chromatographic determination of cholestanol/cholesterol ratio in biological fluids. Its potential usefulness for the follow-up of some liver diseases and its lack of specificity in diagnosing CTX (cerebrotendinous xanthomatosis). Clin Chim Acta 137:305-315, 1984
26. Scheffé H: The Analysis of Variance. London, UK, Wiley, 1959
27. Koopman BJ, Wolthers BG, van der Molen JC, et al: Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis. Clin Chim Acta 152:115-122, 1985
28. Salen G, Berginer V, Shore V, et al: Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N Engl J Med 316:1233-1238, 1987
29. Berginer VM, Berginer J, Korczyn AD. et al: Magnetic resonance imaging in cerebrotendinous xanthomatosis: A prospective clinical and neuroradiological study. J Neurol Sci 122:102-108, 1994
30. Batta AK, Shefer S, Batta M, et al: Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography. J Lipid Res 26:690-698, 1985
31. Bisgaier CL, Essenburg AD, Auerbach BJ, et al: Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J Lipid Res 38:2502-2515, 1997
32. Mamotte CDS, Sturm M, Foo JI, et al: Familial defective apolipoprotein B-100 (FDB): Effect of simvastatin therapy on LDL-receptor binding. Atherosclerosis 125:103-110, 1996
33. Federico A, Dotti MT: Treatment of cerebrotendinous xanthomatosis. Neurology 44:2218, 1994, (letter)